1. Home
  2. Publications
  3. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.

Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.

Bonnet M Bastard M du Cros P Khamraev A Kimenye K Khurkhumal S Hayrapetyan A Themba D Telnov A Sanchez-Padilla E Hewison C Varaine F
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2016 Feb ; 20(2); 177-86. doi: 10.5588/ijtld.15.0962. Epub 2017 01 10

Abstract

BACKGROUND: The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective drugs are not available, and delamanid for patients at high risk of poor outcome.

OBJECTIVE: To identify patients at risk of unfavourable outcomes who may benefit from the new drugs.

METHODS: Retrospective cohort study of treatment outcomes involving four to five effective drugs for 15-24 months in programmes in Uzbekistan, Georgia, Armenia, Swaziland and Kenya between 2001 and 2011.

RESULTS: Of 1433 patients, 48.5% had body mass index (BMI)

CONCLUSION: In our cohort, patients who may benefit from bedaquiline and delamanid represented up to two thirds of all MDR-TB patients.

Link to journal page